up to €20m · Debt · Healthtech · Milan, Italy
Tensive has signed up to €20m in convertible venture debt financing with the European Investment Bank to advance REGENERA, its bioresorbable implant for breast reconstruction after lumpectomy. The Milan-based company says the facility will fund R&D, clinical studies, CE marking, manufacturing scale-up and commercialisation readiness, with first EU approval anticipated in early 2027.
The agreement makes €20m available in two tranches of €8m and €12m, each subject to financial and contractual conditions. Tensive says the EIB commitment covers half of a €40m financing plan and is intended to anchor an ongoing equity raise, so the headline figure is a conditional facility rather than cash already drawn.
From pivotal data to regulatory readiness
REGENERA is a sponge-like polymer scaffold placed in the cavity left when a tumour is removed during breast-conserving surgery. The EIB says healthy tissue grows into the scaffold as the material is absorbed, while the implant remains distinguishable on medical imaging to support radiotherapy targeting and follow-up. The product is still investigational and is not commercially available.
The financing follows Tensive’s July update from its ongoing 94-patient pivotal trial. The company reported good-to-excellent cosmetic outcomes in 94.2% of evaluable cases at 12 months, no interference with ultrasound, MRI or mammography, and improved patient-reported measures for breast satisfaction and cancer worry. Tensive said 87 participants had passed 12 months of follow-up and 30 had reached 24 months; the full dataset was still due for peer-reviewed publication.
Venture debt tied to a regulatory milestone
For a clinical-stage device company, the costly stretch between trial evidence and market launch includes regulatory work, manufacturing readiness and the capacity to supply hospitals. A long-dated facility can extend that runway without requiring Tensive to finance the whole programme through equity, but the staged drawdowns also link access to capital with contractual and financial conditions.
That structure matches the risk profile the EIB describes: medtech companies can struggle to secure conventional long-term loans before regulatory approval because they have development risk and limited collateral. For Tensive, the commercial milestone is not simply producing more implants; it is converting encouraging clinical data into CE marking, repeatable manufacturing and adoption by European surgeons. The remaining equity financing and the expected 2027 regulatory decision therefore remain important execution dependencies.
